Page 3 - Sofinnova Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals – Advances Vision 3×3 to extend global clinical and commercial reach – COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150 million Series B financing. “Our relationship with VISEN is a key element of our Vision 3×3 stra...

Press release content from PR Newswire. The AP news staff was not involved in its creation. VISEN Pharmaceuticals Receives IND Approval to Initiate Phase 2 Clinical Trial of TransCon ™ CNP in Achondroplasia (ACH) in China January 7, 2021 GMT SHANGHAI, Jan. 7, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, introducing the world’s leading treatment methods and drugs into the China market and hoping to provide more Chinese patients quick access to the world’s most advanced and reliable treatment solutions, today annou...